-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Selection -X- _ O
of -X- _ O
effective -X- _ O
viral -X- _ O
siRNA -X- _ O
is -X- _ O
an -X- _ O
indispensable -X- _ O
step -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
siRNA -X- _ O
based -X- _ O
antiviral -X- _ O
therapeutics. -X- _ O
Despite -X- _ O
immense -X- _ O
potential -X- _ O
, -X- _ O
a -X- _ O
viral -X- _ O
siRNA -X- _ O
efficacy -X- _ O
prediction -X- _ O
algorithm -X- _ O
is -X- _ O
still -X- _ O
not -X- _ O
available. -X- _ O
Moreover -X- _ O
, -X- _ O
performances -X- _ O
of -X- _ O
the -X- _ O
existing -X- _ O
general -X- _ O
mammalian -X- _ O
siRNA -X- _ O
efficacy -X- _ O
predictors -X- _ O
are -X- _ O
not -X- _ O
satisfactory -X- _ O
for -X- _ O
viral -X- _ O
siRNAs. -X- _ O
Therefore -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
developed -X- _ O
“VIRsiRNApred” -X- _ B-Intervention
a -X- _ O
support -X- _ O
vector -X- _ O
machine -X- _ O
( -X- _ O
SVM -X- _ O
) -X- _ O
based -X- _ O
method -X- _ O
for -X- _ O
predicting -X- _ O
the -X- _ O
efficacy -X- _ B-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
siRNA. -X- _ I-Outcome
METHODS -X- _ O
: -X- _ O
In -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
employed -X- _ O
a -X- _ O
new -X- _ O
dataset -X- _ O
of -X- _ O
1725 -X- _ O
viral -X- _ O
siRNAs -X- _ O
with -X- _ O
experimentally -X- _ O
verified -X- _ O
quantitative -X- _ O
efficacies -X- _ O
tested -X- _ O
under -X- _ O
heterogeneous -X- _ O
experimental -X- _ O
conditions -X- _ O
and -X- _ O
targeting -X- _ O
as -X- _ O
many -X- _ O
as -X- _ O
37 -X- _ B-Patient
important -X- _ I-Patient
human -X- _ I-Patient
viruses -X- _ I-Patient
including -X- _ I-Patient
HIV -X- _ I-Patient
, -X- _ I-Patient
Influenza -X- _ I-Patient
, -X- _ I-Patient
HCV -X- _ I-Patient
, -X- _ I-Patient
HBV -X- _ I-Patient
, -X- _ I-Patient
SARS -X- _ I-Patient
etc. -X- _ I-Patient
These -X- _ O
siRNAs -X- _ O
were -X- _ O
divided -X- _ O
into -X- _ O
training -X- _ O
( -X- _ O
T -X- _ O
( -X- _ O
1380 -X- _ O
) -X- _ O
) -X- _ O
and -X- _ O
validation -X- _ O
( -X- _ O
V -X- _ O
( -X- _ O
345 -X- _ O
) -X- _ O
) -X- _ O
datasets. -X- _ O
Important -X- _ O
siRNA -X- _ O
sequence -X- _ O
features -X- _ O
including -X- _ O
mono -X- _ O
to -X- _ O
penta -X- _ O
nucleotide -X- _ O
frequencies -X- _ O
, -X- _ O
binary -X- _ O
pattern -X- _ O
, -X- _ O
thermodynamic -X- _ O
properties -X- _ O
and -X- _ O
secondary -X- _ O
structure -X- _ O
were -X- _ O
employed -X- _ O
for -X- _ O
model -X- _ O
development. -X- _ O
RESULTS -X- _ O
: -X- _ O
During -X- _ B-Outcome
10-fold -X- _ I-Outcome
cross -X- _ I-Outcome
validation -X- _ I-Outcome
on -X- _ I-Outcome
T -X- _ I-Outcome
( -X- _ I-Outcome
1380 -X- _ I-Outcome
) -X- _ I-Outcome
using -X- _ I-Outcome
hybrid -X- _ I-Outcome
approach -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
achieved -X- _ I-Outcome
a -X- _ I-Outcome
maximum -X- _ I-Outcome
Pearson -X- _ I-Outcome
Correlation -X- _ I-Outcome
Coefficient -X- _ I-Outcome
( -X- _ I-Outcome
PCC -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
0.55 -X- _ I-Outcome
between -X- _ I-Outcome
predicted -X- _ I-Outcome
and -X- _ I-Outcome
actual -X- _ I-Outcome
efficacy -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
siRNAs. -X- _ I-Outcome
On -X- _ I-Outcome
V -X- _ I-Outcome
( -X- _ I-Outcome
345 -X- _ I-Outcome
) -X- _ I-Outcome
independent -X- _ I-Outcome
dataset -X- _ I-Outcome
, -X- _ I-Outcome
our -X- _ I-Outcome
best -X- _ I-Outcome
model -X- _ I-Outcome
achieved -X- _ I-Outcome
a -X- _ I-Outcome
maximum -X- _ I-Outcome
correlation -X- _ I-Outcome
of -X- _ I-Outcome
0.50 -X- _ I-Outcome
while -X- _ I-Outcome
existing -X- _ I-Outcome
general -X- _ I-Outcome
siRNA -X- _ I-Outcome
prediction -X- _ I-Outcome
methods -X- _ I-Outcome
showed -X- _ I-Outcome
PCC -X- _ I-Outcome
from -X- _ I-Outcome
0.05 -X- _ I-Outcome
to -X- _ I-Outcome
0.18. -X- _ I-Outcome
However -X- _ I-Outcome
, -X- _ I-Outcome
using -X- _ I-Outcome
leave -X- _ I-Outcome
one -X- _ I-Outcome
out -X- _ I-Outcome
cross -X- _ I-Outcome
validation -X- _ I-Outcome
PCC -X- _ I-Outcome
was -X- _ I-Outcome
improved -X- _ I-Outcome
to -X- _ I-Outcome
0.58 -X- _ I-Outcome
and -X- _ I-Outcome
0.55 -X- _ I-Outcome
on -X- _ I-Outcome
training -X- _ I-Outcome
and -X- _ I-Outcome
validation -X- _ I-Outcome
datasets -X- _ I-Outcome
respectively. -X- _ I-Outcome
SVM -X- _ I-Outcome
performed -X- _ I-Outcome
better -X- _ I-Outcome
than -X- _ I-Outcome
other -X- _ I-Outcome
machine -X- _ I-Outcome
learning -X- _ I-Outcome
techniques -X- _ I-Outcome
used -X- _ I-Outcome
like -X- _ I-Outcome
ANN -X- _ I-Outcome
, -X- _ I-Outcome
KNN -X- _ I-Outcome
and -X- _ I-Outcome
REP -X- _ I-Outcome
Tree. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
VIRsiRNApred -X- _ B-Outcome
is -X- _ I-Outcome
the -X- _ I-Outcome
first -X- _ I-Outcome
algorithm -X- _ I-Outcome
for -X- _ I-Outcome
predicting -X- _ I-Outcome
inhibition -X- _ I-Outcome
efficacy -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
siRNAs -X- _ I-Outcome
which -X- _ I-Outcome
is -X- _ I-Outcome
developed -X- _ I-Outcome
using -X- _ I-Outcome
experimentally -X- _ I-Outcome
verified -X- _ I-Outcome
viral -X- _ I-Outcome
siRNAs. -X- _ I-Outcome
We -X- _ O
hope -X- _ O
this -X- _ O
algorithm -X- _ O
would -X- _ O
be -X- _ O
useful -X- _ O
in -X- _ O
predicting -X- _ O
highly -X- _ O
potent -X- _ O
viral -X- _ O
siRNA -X- _ O
to -X- _ O
aid -X- _ O
siRNA -X- _ O
based -X- _ O
antiviral -X- _ O
therapeutics -X- _ O
development. -X- _ O
The -X- _ O
web -X- _ O
server -X- _ O
is -X- _ O
freely -X- _ O
available -X- _ O
at -X- _ O
http -X- _ O
: -X- _ O
/ -X- _ O
/ -X- _ O
crdd.osdd.net -X- _ O
/ -X- _ O
servers -X- _ O
/ -X- _ O
virsirnapred -X- _ O
/ -X- _ O
. -X- _ O

